Clinical Trials Browser

Interventional × Prostatic Neoplasms × vandetanib × Clear all

NCT00937417 2017-04-24

S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

Phase 1 Withdrawn

BreastCNSEndocrineGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Breast Neoplasms, Male, Thyroid Carcinoma, Anaplastic

NCT00686036 2016-12-21

ZENITH

Phase 2 Terminated

17 enrolled 4 charts

Prostatic Neoplasms

NCT00659438 2016-12-05

Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer

Phase 2 Completed

95 enrolled 12 charts

Prostatic Neoplasms

NCT00498797 2016-10-07

E3-Hormone Refractory Prostrate Cancer Taxotere Combination

Phase 2 Completed

86 enrolled 8 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT00757692 2013-02-20

Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.

Phase 2 Completed

Prostatic Neoplasms